Market Overview

KBW: We're Upgrading Chubb Corp

Share:

In a report published Friday, Keefe, Bruyette & Woods analyst Meyer Shields upgraded the rating on Chubb Corp (NYSE: CB) from Underperform to Market Perform, with a $92 price target. The stock has been the "second worst" performer among large-cap P&C insurers, year-to-date.

"We view Chubb as one of the industry's highest-quality insurers. We attribute much of the underperformance to its former large valuation premium relative to its own historical averages, which we saw as vulnerable to disappointment as primary insurance rate increases subsided," Shields said.

While the EPS estimates for 2015 and 2016 were maintained, the 2017 EPS estimate was introduced at $8.70, reflecting expectations of limited top-line growth, modest increase in the core-loss ration and a gradual fading of favorable reserve development, "offset by eventually-rising investment yields and steady share repurchases (about $1.3 billion annually in 2015-2017)," Keefe, Bruyette & Woods reports stated.

Latest Ratings for CB

DateFirmActionFromTo
Oct 2019MaintainsOutperform
Oct 2019MaintainsOutperform
Aug 2019MaintainsEqual-Weight

View More Analyst Ratings for CB
View the Latest Analyst Ratings

Posted-In: Keefe Bruyette & Woods Meyer ShieldsAnalyst Color Upgrades Analyst Ratings

 

Related Articles (CB)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
ELBerenbergReinstates230.0
CBTBairdDowngrades
FBMEvercore ISI GroupUpgrades
FMCBairdUpgrades95.0
MOSCImperial CapitalInitiates Coverage On12.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Goldman Sachs Initiates LifePoint Health With Conviction Buy

GBP/USD Moves Down